ELI LILLY & Co
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
LLY$1,432.29+1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Shareholders' Equity
| Equity of Eli Lilly and Company Shareholders | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Dollars in millions, except per-share data, and shares in thousands) · Common Stock · AdditionalPaid-inCapital · RetainedEarnings · Employee Benefit Trust · Accumulated Other Comprehensive Loss · Common Stock in Treasury(1) · Noncontrolling Interests | |||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||
| Balance at April 1, 2023 | 949,669 | $593.5 | $6,793.1 | $10,639.3 | $(3,013.2) | $(3,777.3) | 402 | $(45.0) | $104.5 | ||||
| Net income (loss) | 1,763.2 | (9.5) | |||||||||||
| Other comprehensive loss, net of tax | (11.4) | ||||||||||||
| Cash dividends declared per share: $2.26 | (2,034.0) | ||||||||||||
| Issuance of stock under employee stock plans, net | 19 | 0.1 | (6.0) | ||||||||||
| Stock-based compensation | 161.5 | ||||||||||||
| Other | (9.5) | ||||||||||||
| Balance at June 30, 2023 | 949,688 | $593.6 | $6,948.6 | $10,368.5 | $(3,013.2) | $(3,788.7) | 402 | $(45.0) | $85.5 | ||||
| Balance at April 1, 2024 | 950,768 | $594.2 | $7,009.5 | $12,553.9 | $(3,013.2) | $(4,299.5) | 365 | $(32.7) | $85.2 | ||||
| Net income (loss) | 2,967.0 | (9.9) | |||||||||||
| Other comprehensive loss, net of tax | (79.0) | ||||||||||||
| Cash dividends declared per share: $2.60 | (2,342.9) | ||||||||||||
| Issuance of stock under employee stock plans, net | 13 | — | (6.4) | ||||||||||
| Stock-based compensation | 211.1 | ||||||||||||
| Other | (1.8) | ||||||||||||
| Balance at June 30, 2024 | 950,781 | $594.2 | $7,214.2 | $13,178.0 | $(3,013.2) | $(4,378.5) | 365 | $(32.7) | $73.5 | ||||
(1) As of June 30, 2024, there was $2.50 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.
| Equity of Eli Lilly and Company Shareholders | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Dollars in millions, except per-share data, and shares in thousands) · Common Stock · AdditionalPaid-inCapital · RetainedEarnings · Employee Benefit Trust · Accumulated Other Comprehensive Loss · Common Stock in Treasury(1) · Noncontrolling Interests | |||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||
| Balance at January 1, 2023 | 950,632 | $594.1 | $6,921.4 | $10,042.6 | $(3,013.2) | $(3,844.6) | 450 | $(50.5) | $125.6 | ||||
| Net income | 3,108.1 | 0.5 | |||||||||||
| Other comprehensive income, net of tax | 55.9 | ||||||||||||
| Cash dividends declared per share: $2.26 | (2,034.0) | ||||||||||||
| Retirement of treasury shares | (2,299) | (1.4) | (748.6) | (2,299) | 750.0 | ||||||||
| Purchase of treasury shares | 2,299 | (750.0) | |||||||||||
| Issuance of stock under employee stock plans, net | 1,355 | 0.9 | (265.5) | (48) | 8.8 | ||||||||
| Stock-based compensation | 292.7 | ||||||||||||
| Other | 0.4 | (3.3) | (40.6) | ||||||||||
| Balance at June 30, 2023 | 949,688 | $593.6 | $6,948.6 | $10,368.5 | $(3,013.2) | $(3,788.7) | 402 | $(45.0) | $85.5 | ||||
| Balance at January 1, 2024 | 949,781 | $593.6 | $7,250.4 | $10,312.3 | $(3,013.2) | $(4,327.0) | 402 | $(44.2) | $91.8 | ||||
| Net income (loss) | 5,209.9 | (15.0) | |||||||||||
| Other comprehensive loss, net of tax | (51.5) | ||||||||||||
| Cash dividends declared per share: $2.60 | (2,342.9) | ||||||||||||
| Issuance of stock under employee stock plans, net | 1,000 | 0.6 | (406.7) | (37) | 11.5 | ||||||||
| Stock-based compensation | 370.5 | ||||||||||||
| Other | (1.3) | (3.3) | |||||||||||
| Balance at June 30, 2024 | 950,781 | $594.2 | $7,214.2 | $13,178.0 | $(3,013.2) | $(4,378.5) | 365 | $(32.7) | $73.5 | ||||
(1) As of June 30, 2024, there was $2.50 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.